Document is current
Any future updates will be listed below
-
Authors
Li, Dan
Wang, Ruixue
Liang, Tianyuzhou https://orcid.org/0009-0003-9291-1142
Ren, Hua https://orcid.org/0000-0002-8809-7972
Park, Chaelee https://orcid.org/0000-0002-3909-0096
Tai, Chin-Hsien https://orcid.org/0000-0003-4766-0535
Ni, Weiming https://orcid.org/0000-0002-4786-7782
Zhou, Jing https://orcid.org/0000-0001-7935-5100
Mackay, Sean
Edmondson, Elijah https://orcid.org/0000-0002-6106-3705
Khan, Javed https://orcid.org/0000-0002-5858-0488
Croix, Brad St https://orcid.org/0000-0002-6246-0374
Ho, Mitchell https://orcid.org/0000-0002-9152-5405
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Z01 BC010891, ZIA BC010891)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 24 December 2022
Accepted: 11 September 2023
First Online: 22 September 2023
Competing interests
: M.H., R.W., B.S.C., and D.L. are inventors on international patent application no. PCT/US2020/056601 (WO/2021/081052) assigned to the NIH, “High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors”. W.N., J.Z., and S.M. are employed by and have equity ownership in IsoPlexis. All authors declare no other competing interests.
